艾伯维(ABBV.US)收购的Cerevel(CERE.US)达成帕金森病药物晚期阶段主要目标

智通财经04-18

智通财经APP获悉，艾伯维(ABBV.US)的收购标的Cerevel Therapeutics(CERE.US)周四宣布，其每日一次的帕金森病口服候选药物tavapadon在一项作为联合疗法的关键性三期试验中达成主要目标。该公司说，针对帕金森病晚期成人患者的TEMPO-3研究表明，在主要终点方面，他伐帕东与脑部疗法左旋多巴联合用药与安慰剂加左旋多巴相比，具有临床意义和显著的统计学差异。这项为期27...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2428084599?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-18 21:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2428084599","market":"us","top_or_hot":-1,"title":"艾伯维(ABBV.US)收购的Cerevel(CERE.US)达成帕金森病药物晚期阶段主要目标","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，艾伯维(ABBV.US)的收购标的Cerevel Therapeutics(CERE.US)周四宣布，其每日一次的帕金森病口服候选药物tavapadon在一项作为联合疗法的关键性三期试验中达成主要目标。该公司说，针对帕金森病晚期成人患者的TEMPO-3研究表明，在主要终点方面，他伐帕东与脑部疗法左旋多巴联合用药与安慰剂加左旋多巴相比，具有临床意义和显著的统计学差异。这项为期27...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404182128598b3637a2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>艾伯维(ABBV.US)收购的Cerevel(CERE.US)达成帕金森病药物晚期阶段主要目标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n艾伯维(ABBV.US)收购的Cerevel(CERE.US)达成帕金森病药物晚期阶段主要目标\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-18 21:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404182128598b3637a2&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，艾伯维(ABBV.US)的收购标的Cerevel Therapeutics(CERE.US)周四宣布，其每日一次的帕金森病口服候选药物tavapadon在一项作为联合疗法的关键性三期试验中达成主要目标。该公司说，针对帕金森病晚期成人患者的TEMPO-3研究表明，在主要终点方面，他伐帕东与脑部疗法左旋多巴联合用药与安慰剂加左旋多巴相比，具有临床意义和显著的统计学差异。这项为期27...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404182128598b3637a2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0211328371.USD","symbol_name":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404182128598b3637a2&s=b","article_id":"2428084599","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404182128598b3637a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2428084599","pubTimestamp":1713446711,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"智通财经APP获悉，艾伯维的收购标的Cerevel Therapeutics周四宣布，其每日一次的帕金森病口服候选药物tavapadon在一项作为联合疗法的关键性三期试验中达成主要目标。Cerevel希望利用这些研究结果支持未来的他伐帕东监管申请。该候选药物在帕金森病中的两项后期单一疗法试验的顶线数据预计将于2024年下半年公布。去年12月，艾伯维同意以87亿美元收购Cerevel。据悉，艾伯维针对Cerevel的全现金收购预计将于2024年中期完成。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","ABBV":"艾伯维公司","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","CERE":"Cerevel Therapeutics Holdings, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","BK4566":"资本集团","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","BK4559":"巴菲特持仓","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0882574055.USD":"富达全球健康医疗A ACC","BK4550":"红杉资本持仓","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B"},"translate_title":"Cerevel (CERE.US) acquired by AbbVie (ABBV.US) achieves the main goal of late-stage Parkinson's disease drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"CERE":1},"content_text":"智通财经APP获悉，艾伯维(ABBV.US)的收购标的Cerevel Therapeutics(CERE.US)周四宣布，其每日一次的帕金森病口服候选药物tavapadon在一项作为联合疗法的关键性三期试验中达成主要目标。该公司说，针对帕金森病晚期成人患者的TEMPO-3研究表明，在主要终点方面，他伐帕东与脑部疗法左旋多巴联合用药与安慰剂加左旋多巴相比，具有临床意义和显著的统计学差异。这项为期27周、针对507名患者的研究将无运动障碍总“开启”时间与基线假设相比的变化作为主要终点，结果显示，与安慰剂对照组(1.7小时对0.6小时)相比，服药组的“开启”时间增加了1.1小时。此外，与安慰剂对照组相比，他伐帕东加左旋多巴组的关键次要终点“关闭”时间也具有有统计学意义的显著缩短。关于安全性，该公司补充说，研究药物的耐受性良好，大多数不良反应程度为轻度至中度。Cerevel希望利用这些研究结果支持未来的他伐帕东监管申请。该候选药物在帕金森病中的两项后期单一疗法试验的顶线数据预计将于2024年下半年公布。去年12月，艾伯维同意以87亿美元收购Cerevel。由于Cerevel是一家领先的精神分裂症药物开发商，其竞争对手Reviva Pharmaceuticals(RVPH.US)和施贵宝(BMY.US)在3月收购的Karuna Therapeutics也随之上涨。据悉，艾伯维针对Cerevel的全现金收购预计将于2024年中期完成。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428084599"}